A look into the 340B explosion of growth as Gilead and J&J join more than a dozen peers setting their own terms
As a new report documents the explosive growth of a federal program providing discounted drugs for low-income Americans, two more large pharma companies — Gilead and Johnson & Johnson — will place new restrictions around their policies for the program, known as 340B.
Including Gilead and J&J, a total of 16 pharma companies have now reworked their 340B operations over the last several years as lawsuits have sought to constrain the firms from what they see as a ballooning portion of the US prescription drug market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.